tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| David-Neto E et al. | Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. | 2017 | Transplantation | pmid:27798513 |
| Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
| Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
| Lawsin L and Light JA | Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. | 2003 | Transplantation | pmid:12544890 |
| Hodge G et al. | Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. | 2010 | Transplantation | pmid:20559033 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Fujita T et al. | Prolonged survival of rat skin allograft by treatment with FK506 ointment. | 1997 | Transplantation | pmid:9326422 |
| Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
| Ashokkumar C et al. | Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. | 2011 | Transplantation | pmid:21747326 |
| Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Tzakis AG et al. | Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. | 2003 | Transplantation | pmid:12792506 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
| Castells L et al. | Liver transplantation in HIV-HCV coinfected patients: a case-control study. | 2007 | Transplantation | pmid:17297413 |
| Alhamad T et al. | Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. | 2017 | Transplantation | pmid:28422926 |
| Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
| Khanna AK | Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. | 2000 | Transplantation | pmid:10972232 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Sofi AA et al. | Bullous pemphigoid associated with acute renal allograft rejection. | 2010 | Transplantation | pmid:20145531 |
| Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Demmers MW et al. | Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. | 2014 | Transplantation | pmid:24157471 |
| Dickenmann MJ et al. | Blood eosinophilia in tacrolimus-treated patients: an indicator of Pneumocystis carinii pneumonia. | 1999 | Transplantation | pmid:10589963 |
| Thorp M et al. | The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. | 2000 | Transplantation | pmid:10762229 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| Klein IH et al. | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907418 |
| Ringe B et al. | A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. | 2001 | Transplantation | pmid:11258429 |
| Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
| Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
| Pascual J et al. | Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. | 2011 | Transplantation | pmid:21336083 |
| Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Konrad T et al. | Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. | 2000 | Transplantation | pmid:10852599 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Letavernier E et al. | Proteinuria following a switch from calcineurin inhibitors to sirolimus. | 2005 | Transplantation | pmid:16314786 |
| Wai LE et al. | Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. | 2008 | Transplantation | pmid:18192925 |
| Herold KC et al. | Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. | 1993 | Transplantation | pmid:7678356 |